

Literatura

- Atiq F, Fijnvandraat K, van Galen KPM, et al. BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease. *Am J Hematol.* 2019; 94: 201–205.
- Baroncini L, Peake I, Schneppenheim R, et al. Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3Winters-IPS. *Blood Adv.* 2021; 10: 2987–3001.
- Berger J, Schwartz J, Ramachandran S, et al. Review of von Willebrand Disease and acquired von Willebrand syndrome for patients undergoing cardiac surgery. *J Cardiothorac Vasc Anesth.* 2019; 33: 3446–3457.
- Berntorp E. Erik von Willebrand. *Thromb Res.* 2007; 120: 3–4.
- Bharati KP, Prashanth UR. Von Willebrand disease: an overview. *Indian J Pharm Sci.* 2011; 73: 7–16.
- Bowyer AE, Goodfellow KJ, Seidel H, et al. Evaluation of a semi-automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers. *Res Pract Thromb Haemost.* 2018; 2: 790–799.
- Brignardello-Petersen R, El Alayli A, Husainat N, et al. Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature. *Blood Adv.* 2022; 6: 228–237.
- Brunclikova M., Dobrotova M., Holly P, et al. Úspešná profylaxia krvácania purifikovaným koncentrátom von Willebrandovho faktora pri ťažkej forme von Willebrandovej choroby – vlastné skúsenosti. *Vask med.* 2021; 13: 35–40.
- Bryckaert M, Rosa JP, Denis CV, et al. Of von Willebrand factor and platelets. *Cell Mol Life Sci.* 2015; 72: 307–326.
- Budde U, Schneppenheim R. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura. *Hamostaseologie* 2014; 34: 215–225.
- Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. *Blood Adv.* 2021; 5: 301–325.
- Crist RA, Heikal NM, Rodgers GM, et al. Evaluation of a new commercial method for von Willebrand factor multimeric analysis. *Int J Lab Hem.* 2018; 40: 586–591.
- Cumming A, Grundy P, Keeney S, et al. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. *Thromb Haemost.* 2006; 96: 630–641.
- Curnow J, Pasalic L, Favalaro EJ. Treatment of von Willebrand Disease. *Semin Thromb Hemost.* 2016; 42: 133–146.
- Dahiya DS, Kichloo A, Zain EA, et al. Heyde Syndrome: An Unusual Cause of Gastrointestinal Bleeding. *J Investig Med High Impact Case Rep.* 2021; 9: 2324709621997279.
- de Jong A, Eikenboom J. Developments in the diagnostic procedures for von Willebrand disease. *J Thromb Haemost.* 2016; 14: 449–460.
- de Meyer SF, Vanhoorelbeke K, Chuah MK, et al. Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. *Blood* 2006; 107: 4728–4736.
- Denis CV, Susen S, Lenting PJ. Von Willebrand disease: what does the future hold? *Blood* 2021; 137: 2299–2306.

- Dong X, Leksa NC, Chhabra ES, et al. The von Willebrand factor D'D3 assembly and structural principles for factor VIII binding and concatemer biogenesis. *Blood* 2019; 133: 1523–1533.
- Dorgalaleh A, Tabibian S, Shams M, et al. Von Willebrand disease in Iran: diagnosis and management. *Ann Blood* 2018; 3: 4.
- Eikenboom J, Federici AB, Dirven RJ, et al.; MCMDM-1VWD Study Group. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. *Blood* 2013; 121: 2336–2339.
- Eikenboom JC. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. *Best Pract Res Clin Haematol.* 2001; 14: 365–379.
- Elbatarny M, Mollah S, Grabell J, et al. Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. *Haemophilia* 2014; 20: 831–835.
- Favaloro EJ, Bonar R, Chapman K, et al. Differential sensitivity of von Willebrand factor (VWF) „activity“ assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. *J Thromb Haemost.* 2012; 10: 1043–1054.
- Favaloro EJ, Franchini M, Lippi G. Biological therapies for von Willebrand Disease. *Expert Opin Biol Ther.* 2012; 12: 551–564.
- Favaloro EJ, Oliver S. Evaluation of a new commercial von Willebrand factor multimer assay. *Haemophilia* 2017; 23: 373–377.
- Favaloro EJ, Pasalic L, Curnow J. Diagnosis and management of von Willebrand disease in Australia. *Annals of Blood* 2018; 3: 31.
- Favaloro EJ, Pasalic L, Curnow J. Laboratory tests used to help diagnose von Willebrand disease: an update. *Pathology* 2016; 48: 303–318.
- Favaloro EJ. Diagnosing von Willebrand disease: a short history of laboratory milestones and innovations, plus current status, challenges, and solutions. *Semin Thromb Hemost.* 2014; 40: 551–570.
- Favaloro, E. J. Rare forms of von Willebrand disease. *Ann Transl Med.* 2018; 6: 345–345.
- Federici AB, Castaman G, Mannucci PM. Guidelines for diagnosis and treatment of von Willebrand disease. *Thromb Haemost.* 2000; 84: 160–174.
- Franchini M, Crestani S, Frattini F, et al. ABO blood group and von Willebrand factor: biological implications. *Clin Chem Lab Med.* 2014; 52: 1273–1276.
- Franchini M, Mannucci PM. Acquired von Willebrand syndrome: focused for hematologists. *Haematologica* 2020; 105: 2032–2037.
- Franchini M. The Interface between Immunotransfusion and Hemostasis and Thrombosis Testing. *Methods Mol Biol.* 2017; 1646: 43–56.
- Fu H, Jiang Y, Yang D, et al. Flow-induced elongation of von Willebrand factor precedes tension-dependent activation. *Nat Commun.* 2017; 8: 324.
- Fukuhara K, Kondo T, Miyoshi H, et al. Rotational thromboelastometry-guided perioperative management of coagulation in a patient with Heyde's syndrome undergoing transcatheter aortic valve implantation. *JA Clin Rep.* 2019; 5: 3.
- Gadisseur A, Michiels JJ. Advances in the Diagnosis and Classification of von Willebrand Disease. *Acta Haematologica* 2009; 121: 67–70.
- Goltstein LCMJ, Rooijackers MJP, Görtjes NCC, et al. Reduction of Gastrointestinal Bleeding in Patients With Heyde Syndrome Undergoing Transcatheter Aortic Valve Implantation. *Circ Cardiovasc Interv.* 2022; 15: 011848.

- Goudemand J, Bridey F, Claeysens S, et al. Management of von Willebrand disease with a factor VIII-poor von Willebrand factor concentrate: Results from a prospective observational post-marketing study. *J Thromb Haemost*. 2020; 18: 1922–1933.
- Gouider E, Klukowska A, Maes P, et al. Efficacy and safety of von Willebrand factor concentrate almost devoid of factor VIII (Wilfactin®) in paediatric patients under 6 years of age with severe von Willebrand disease. *Blood Transfus*. 2023; 21: 83–92.
- Haberichter SL. von Willebrand factor propeptide: biology and clinical utility. *Blood* 2015; 126: 1753–1761.
- Hassan MI, Saxena A, Ahmad F. Structure and function of von Willebrand factor. *Blood Coagul Fibrinolysis* 2012; 23: 11–22.
- Hayward CP, Moffat KA, Graf L. Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges. *Int J Lab Hematol*. 2014; 36: 334–340.
- Hazendonk HCAM, Heijdra JM, de Jager NCB, et al. Analysis of current perioperative management with Haemate® P/Humate P® in von Willebrand disease: Identifying the need for personalized treatment. *Haemophilia* 2018; 24: 460–470.
- Heijdra JM, Cnossen MH, Leebeek FWG. Current and Emerging Options for the Management of Inherited von Willebrand Disease. *Drugs* 2017; 77: 1531–1547.
- Horiuchi H, Doman T, Kokame K, et al. Acquired von Willebrand syndrome associated with cardiovascular diseases. *J Atheroscler Thromb*. 2019; 26: 303–314.
- Christopher NG, Motto DG, di Paola J. Diagnostic approach to von Willebrand disease. *Blood* 2015; 125: 2029–2037.
- James AH, Konkle BA, Kouides P, et al. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. *Haemophilia* 2015; 21: 81–87.
- James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. *Blood Adv*. 2021; 5: 228–300.
- Janbain M, Kouides P. Managing Pregnant Women with Hemophilia and von Willebrand Disease: How Do We Provide Optimum Care and Prevent Complications? *Int J Womens Health* 2022; 14: 1307–1313.
- Jimenez-Yuste V, Núñez L, Alvarez-Roman MT, et al. Efficacy and safety evaluation of Fanhdi®, a plasma-derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study. *Haemophilia* 2022; 28: 23–27.
- Kaur V, Elghawy O, Deshpande S, et al. Von Willebrand disease: A guide for the internist. *Cleve Clin J Med*. 2024; 91: 119–127.
- Kruse-Jarres R, Johnsen JM. How I treat type 2B von Willebrand disease. *Blood* 2018; 131: 2272.
- Kubisz P, et al. *Hematológia a transfuziológia*. Bratislava: Grada Slovakia 2006.
- Kubisz P, Sokol J, Simurda T, et al. Diagnosis and management of von Willebrand disease in Slovakia. *Annals of Blood* 2018; 3: 1–6.
- Laffan M, Sathar J, Johnsen JM. Von Willebrand disease: Diagnosis and treatment, treatment of women, and genomic approach to diagnosis. *Haemophilia* 2021; 27: 66–74.
- Leebeek FW, Eikenboom JC. Von Willebrand's Disease. *N Engl J Med*. 2016; 375: 2067–2080.
- Leebeek FWG, Atiq F. How I manage severe von Willebrand disease. *Br J Haematol*. 2019; 187: 418–430.
- Leebeek FWG, Duvekot J, Kruip MJHA. How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease. *Blood* 2020; 136: 2143–2150.

- Lemaitre A, Nouadje G, Beaulieu Bautista H, et al. Clinical evaluation of the Hydragel 5 von Willebrand multimers of Sebia. *Clin Chem Lab Med.* 2017; 55: 706.
- Lenting PJ, Christophe OD, Denis CV. Von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. *Blood* 2015; 125: 2019–2028.
- Lillicrap D. Von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. *Blood* 2013; 122: 3735–3740.
- Lourdusamy D, Mupparaju VK, Sharif NF, et al. Aortic stenosis and Heyde's syndrome: A comprehensive review. *World J Clin Cases* 2021; 9: 7319–7329.
- Machin N, Ragni MV. Recombinant vs plasma-derived von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease. *Blood Adv.* 2020; 4: 3234–3238.
- Mei ZW, van Wijk XMR, Pham HP, et al. Role of von Willebrand Factor in COVID-19 Associated Coagulopathy. *J Appl Lab Med.* 2021; 6: 1305–1315.
- Miesbach W, Berntorp E. Translating the success of prophylaxis in haemophilia to von Willebrand disease. *Thromb Res.* 2021; 199: 67–74.
- Miesbach W, Berntorp E. Von Willebrand disease – the 'Dos' and 'Don'ts' in surgery. *Eur J Haematol.* 2017; 98: 121–127.
- Miesbach W, Krekeler S, Wolf Z, et al. Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study. *Thromb Res.* 2015; 135: 479–484.
- Miesbach W. Perioperative management for patients with von Willebrand disease: Defining the optimal approach. *Eur J Haematol.* 2020; 105: 365–377.
- Michalová R, Šimonová R, Michalová R jr., et al. Heydeho syndróm. *Gastroenterologie a hepatologie* 2021; 4.
- Michiels JJ, Hermans C, Smejkal P, et al. Von Willebrand Disease (VWD): Diagnostic Differentiation of Pseudo, Mild, Moderate to Severe VWD Type 1 and 2 by a DDAVP Challenge Test on Top of the ISTH Classification. *Thromb Haemost Res.* 2020; 4: 1040.
- Michiels JJ, Smejkal P, Penka M, et al. Diagnostic differentiation of von Willebrand disease types 1 and 2 by von Willebrand factor multimer analysis and DDAVP challenge test. *Clin Appl Thromb Hemost.* 2017; 23: 518–531.
- Mondal S, Hollander KN, Ibekwe SO, et al. Heyde Syndrome-Pathophysiology and Perioperative Implications. *J Cardiothorac Vasc Anesth.* 2021; 35: 3331–3339.
- Muñoz Vargas BA, Contreras Valero SJ, Aragon Mendoza RL, et al. Von Willebrand Disease and Pregnancy: Management Protocol From Labor to the Postpartum Period. *Cureus* 2024; 16: 53465.
- Nilsson IM. The history of von Willebrand disease. *Haemophilia* 1999; 5: 7–11.
- O'Donnell JS, Lavin M. Perioperative management of patients with von Willebrand disease. *Hematology Am Soc Hematol Educ Program* 2019; 2019: 604–609.
- Othman M, Gresele P. Guidance on the diagnosis and management of platelet-type von Willebrand disease: A communication from the Platelet Physiology Subcommittee of the ISTH. *J Thromb Haemost.* 2020; 18: 1855–1858.
- Patzke J, Budde U, Huber A, et al. Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin. *Blood Coagul Fibrinolysis* 2014; 25: 860–870.
- Peyvandi F, Castaman G, Gresele P, et al. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. *Blood Transfus.* 2019; 17: 391–398.
- Peyvandi F, Garagiola I, Menegatti M. Gynecological and obstetrical manifestations of inherited bleeding disorders in women. *J Thromb Haemost.* 2011; 9: 236–245.

- Peyvandi F, Kouides P, Turecek PL, et al. Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor. *Blood Rev.* 2019; 38: 100572.
- Peyvandi F, Mamaev A, Wang JD, et al. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. *J Thromb Haemost.* 2019; 17: 52–62.
- Platton S, Baker P, Bowyer A, et al. Guideline for laboratory diagnosis and monitoring of von Willebrand disease: A joint guideline from the United Kingdom Haemophilia Centre Doctors' Organisation and the British Society for Haematology. *Br J Haematol.* 2024; 204: 1714–1731.
- Roberts JC, Flood VH. Laboratory diagnosis of von Willebrand disease. *Int J Lab Hematol.* 2015; 37: 11–17.
- Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. *J Thromb Haemost.* 2010; 8: 2063–2065.
- Sabih A, Babiker HM. Von Willebrand Disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing 2024 [online]. Dostupné na: <https://www.ncbi.nlm.nih.gov/books/NBK459222/>
- Sami SS, Al-Araji SA, Ragnath K. Review article: Gastrointestinal angiodysplasia – pathogenesis, diagnosis and management. *Aliment Pharmacol Ther.* 2013; 9: 15–34.
- Sanders YV, Groeneveld D, Meijer K, et al. WiN study group. von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. *Blood* 2015; 125: 3006–3013.
- Seidel H, Westhofen P, Bautista H, et al. Clinical evaluation of the sebia hydragel von Willebrand factor assay in comparison to electrophoresis and blotting based multimer analysis, *Res Pract Thromb Haemost.* 2017; 1: 717–718.
- Seidizadeh O, Baronciani L, Lillicrap D, et al. Application of genetic testing for the diagnosis of von Willebrand disease. *J Thromb Haemost.* 2024; 22: 2115–2128.
- Seth Chhabra E, Liu T, Kulman J, et al. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. *Blood* 2020; 135: 1484–1496.
- Shanmukhaiah C, Jijina F, Kannan S, et al. Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature. *Haemophilia* 2022; 28: 286–291.
- Simurda T, Dobrotova M, Skornova I, et al. Successful Use of a Highly Purified Plasma von Willebrand Factor Concentrate Containing Little FVIII for the Long-Term Prophylaxis of Severe (Type 3) von Willebrand's Disease. *Semin Thromb Hemost.* 2017; 43: 639–641.
- Sinha S, Castro D, Shakil S. Medical Management of Heyde Syndrome. *Cureus* 2021; 13: 12551.
- Skornova I, Simurda T, Stasko J, et al. Multimer Analysis of Von Willebrand Factor in Von Willebrand Disease with a Hydrasys Semi-Automatic Analyzer-Single-Center Experience. *Diagnostics* 2021; 11: 2153.
- Smejkal P, Matýšková M, Penka M. Von Willebrandova choroba. *Vnitř. Lék.* 2008; 54: 257–264.
- Staško J, Sokol J, Dobrotová M, et al. P. Willebrandova choroba – profylaxia a liečba. *Vask med.* 2016; 8: 116–121.
- Szanto T, Lassila R, Funding E, et al. Von Willebrand disease – the Nordic perspective. *Annals of Blood* 2018; 3: 2.
- Škorňová I, Slavík L, Šimurda T, et al. Hemostáza; laboratorne metódy, ich využitie a interpretácia vo vybraných klinických situáciach/laboratorní metody, jejich využití a interpretace ve vybraných klinických situacích. 3. doplněné vydání. Olomouc: Univerzita Palackého 2024.

- Škorňová I, Staško J, Hollý, et al. Von Willebrandova choroba – porovnanie dvoch metód analýzy multimérov von Willebrandovho faktora. *Transfúze a hematologie dnes* 2021; 27: 42.
- Tiede A. Diagnosis and treatment of acquired von Willebrand syndrome. *Thromb Res.* 2012; 130: 2–6.
- VanderMeulen H, Arya S, Nersesian S, et al. What have we learned about the patient's experience of von Willebrand disease? A focus on women. *Hematology Am Soc Hematol Educ Program* 2022; 2022: 631–636.
- Vangenechten I, Gadisseur A. Improving diagnosis of von Willebrand disease: Reference ranges for von Willebrand factor multimer distribution. *Res Pract Thromb Haemost.* 2020; 4: 1024–1034.
- Vangenechten I, Smejkal P, Zavrelva J, et al. Analysis of von Willebrand Disease in the „Heart of Europe“. *TH Open* 2022; 6: 335–346.
- Vasse M, Francois D, Ligneel T, et al. „Interest of the new rapid test Hydragel 5 von willebrand multimers“ for the analysis of von willebrand multimers. *Int J Lab Hem.* 2016; 38: 113.
- Waldschmidt L, Seiffert M. Heyde syndrome: treat aortic valve disease to stop gastrointestinal bleeding? *Eur Heart J.* 2023; 44: 3178–3180.
- Windyga J, von Depka-Prondzinski M; European Wilate® Study Group. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. *Thromb Haemost.* 2011; 105: 1072–1079.
- Zolkova J, Sokol J, Simurda T, et al. Genetic Background of von Willebrand Disease: History, Current State, and Future Perspectives. *Semin Thromb Hemost.* 2020; 46: 484–500.
- Žolková J, Sokol J, Šimurda T, et al. The Importance and Complications of Sequencing of von Willebrand Gene in Von Willebrand Disease. *Acta Medica Martiniana* 2019; 19: 5–11.